Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]Ga DOTA-5G PET/CT in Metastatic Lobular Breast Cancer
NCT07020806Phase 1Recruiting
- Sponsor
- University of California, Davis
- Start
- Nov 2025
- Primary completion
- Jun 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [68Ga]Ga DOTA-5G in Invasive Lobular Carcinoma (ILC), sponsored by University of California, Davis. Primary endpoints: Ability of [68Ga]Ga DOTA-5G PET/CT imaging to detect lesions at 2 hours and Incidence of adverse events using CTCAE v 5.0 up to 7 days. Started Nov 2025; status: recruiting.
02
Drugs
[68Ga]Ga DOTA-5G
03
Conditions
Invasive Lobular Carcinoma (ILC)
Beyond the preview
Go deeper on NCT07020806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07020806.